City Therapeutics, the RNA interference biotech developing therapies for thromboembolic diseases, has pulled off an upsized IPO, raising $200 million that will be split across its pipeline. The company will begin trading on the Nasdaq Friday under the ticker CTY, after offering over 11 million shares at $18 apiece, according to the Thursday press release. Originally, City had targeted a sale of about 9.7 million shares for $158.3 million but has exceeded that, and another 1.6